メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
研究推進機構先端抗体医薬開発センター
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(2)
プロジェクト
(2)
研究成果
(8)
フィンガープリント
研究推進機構先端抗体医薬開発センターが活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
CpG ODN
70%
Respiratory Syncytial Virus
64%
Gut Microbiota
61%
Recombinant Glycoprotein
52%
CD4+ T Cells
42%
Upper Respiratory Tract
39%
Virus Challenge
38%
Pre-existing Immunity
35%
Antigen-specific Response
35%
Respiratory Syncytial Virus Infection
35%
Intranasal Vaccine
35%
Intranasal Immunization
35%
Subsequent Generations
35%
Maternal Microbiome
35%
Receptor-binding Domain
35%
Epigenetic Modification
35%
Eosinophilia
35%
Hemagglutinin
35%
Gut Microbiome
35%
Food Allergy
35%
Fusion Protein
35%
Glycolate
35%
Glycoprotein
35%
Before Pregnancy
35%
Metabolism
35%
Non-glycosylated
35%
Vitamin B2
35%
Anti-PEG Antibodies
35%
Protein Vaccine
35%
MRNA-LNP
31%
Messenger RNA Vaccine
31%
Lung Weight
25%
Antibiotics
22%
Vaccine Platform
21%
T Helper 1
20%
Specific Antibodies
17%
Vaccine Target
17%
Nanoparticle Vaccine
15%
COVID-19
14%
Infectious Diseases
14%
Influenza Virus
14%
Serum IgE
11%
Methylation Status
11%
Lower Respiratory Tract
11%
Antibiotic Treatment
11%
Vaccine Antigen
11%
Vaccination
11%
Highly Effective
10%
Dietary Vitamins
8%
Combination Vaccine
8%
Adverse Reactions
8%
Lung
8%
Anti-PEG IgM
7%
Ionizable Lipids
7%
H5N1 Virus
7%
Mucosal IgA
7%
Initial Infection
7%
Previous Infection
7%
Adjuvant-free
7%
SARS-CoV-2 Infection
7%
Antigen-specific Immune Response
7%
Infected Mice
7%
Systemic Immunity
7%
Carrier Protein
7%
Mucosal Immunity
7%
Vaccine Effectiveness
7%
Novel Fusion
5%
Severe Respiratory Failure
5%
Offspring Health
5%
F1 Progeny
5%
Butyric Acid-producing Bacteria
5%
Maternal Environment
5%
Lamina Propria Lymphocytes
5%
Acid Concentration
5%
Cecal Contents
5%
Intestinal Lamina Propria
5%
Butyric Acid
5%
Lower Respiratory Tract Infection
5%
Host Immune Response
5%
Effective Strategies
5%
Later Life
5%
DNA Methylation (DNAm)
5%
Neutralizing Antibodies
5%
Environmental Factors
5%
Older Adults
5%
Surface Antigen
5%
Fecal Excretion
5%
Novel Environment
5%
Stress Response
5%
Gut Microbiota Composition
5%
T Helper 2
5%
Food-related
5%
Lung Tissue Damage
5%
Immunology and Microbiology
CpG Oligodeoxynucleotide
70%
Intestine Flora
70%
Glycoprotein
70%
Human Respiratory Syncytial Virus
64%
Antigen Specificity
63%
T-Helper Cell
42%
Immune Response
42%
Upper Respiratory Tract
38%
Microbial Metabolism
35%
Respiratory Syncytial Virus Infection
35%
Receptor Binding
35%
Hemagglutinin
35%
Epigenetic Modification
35%
Food Allergy
35%
Lung Weight
35%
RNA Vaccine
35%
Antibodies
24%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
Progeny
20%
T Helper 1 Cell
18%
Lower Respiratory Tract
17%
Neutralizing Antibody
17%
Adjuvant
16%
Infectious Disease
14%
Influenzavirus A
14%
Cytokine
11%
COVID-19
11%
Adoptive Immunity
11%
Immunoglobulin M
11%
Immunology
10%
Mucosal Immunity
7%
Membrane Transport Protein
7%
Spike
7%
Systemic Immunity
7%
Immunoglobulin A
7%
Pulmonary Inflammation
6%
Metabolite
5%
T Helper 2 Cell
5%
Blood Plasma
5%
Membrane Antigen
5%
Microorganism
5%
Methylation
5%
Lamina Propria
5%
Immunocompetent Cell
5%
DNA Methylation
5%
Immunoglobulin E
5%
Conception
5%
Lymphocyte
5%
Pharmacology, Toxicology and Pharmaceutical Science
Human Respiratory Syncytial Virus
100%
CpG Oligodeoxynucleotide
70%
Glycoprotein
70%
Respiratory Tract Disease
47%
Respiratory Tract
38%
Guanine Nucleotide Binding Protein
38%
Riboflavin Deficiency
35%
Respiratory Syncytial Virus Infection
35%
Intestine Flora
35%
Eosinophilia
35%
Glycolic Acid
35%
Microorganism
35%
Mucin
35%
Interleukin 13
35%
Riboflavin
23%
Antibodies
12%
Adjuvant
9%
Pneumonia
6%
Adverse Event
6%
Combination Vaccine
6%
Vitamin B12
5%
Neutralizing Antibody
5%
Vitamin Deficiency
5%
Membrane Antigen
5%
Folic Acid
5%
Antibiotics
5%
Tissue Injury
5%
Immunopathology
5%